UNSPSC 51111851: Histrelin

This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H50H3S3W74. European Medicines Agency schedules Histrelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08046MIG. Histrelin generally arises in the molecular formula C66H86N18O12.

The term HISTRELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) HISTRELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule histrelin under HS 29371900 and SITC 54154. As of Q4 2014, HISTRELIN remains the US FDA Preferred Term for this commodity. Histrelin bears US NLM identifiers UMLS ID C0121902 and NCI Concept Code C74270.

UNSPSC 51111851 Histrelin, a Commodity code, encompasses pharmaceutical products supplied through state and local cooperative purchasing agreements, specifically generic multi-source drugs and over-the-counter medications distributed to government healthcare facilities and supporting institutions. State and local governments procure histrelin and related pharmaceutical commodities primarily through cooperative purchasing vehicles administered by state departments, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving as a representative buyer consolidating demand across multiple participating states and local jurisdictions. The procurement model emphasizes supply chain compliance, requiring vendors to maintain relationships with authorized wholesalers, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and deliver products meeting FDA standards with documented expiration and shelf-life guarantees.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026, is the most recent documented opportunity under this code and encompasses Minnesota, Oregon, and other participating member jurisdictions. The solicitation evaluates vendors primarily on price competitiveness (75 percent of scoring), with secondary weight on fixed pricing structure (10 percent), compliance with data format and EDI requirements (5 percent each), and willingness to accept a 3 percent administrative fee (5 percent). Vendors must submit detailed product information including National Drug Codes, SKUs, UPCs, and packaging configurations through the ePro procurement system, maintain comprehensive insurance coverage ranging from $2 million to $5 million depending on coverage type, and agree to performance penalties of $200 to $1,500 per violation for reporting or onboarding failures. The contract term runs two years for new vendors, with optional extensions and incumbent amendments aligning through June 30, 2028, and award awards may be structured as sole, dual, or multi-awards based on therapeutic and patient-safety considerations.